Psychedelic Psychiatry's Brave New World
- PMID: 32243793
- DOI: 10.1016/j.cell.2020.03.020
Psychedelic Psychiatry's Brave New World
Abstract
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Copyright © 2020 Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Psychedelic Psychiatry's Brave New World.Front Psychiatry. 2020 Nov 26;11:594077. doi: 10.3389/fpsyt.2020.594077. eCollection 2020. Front Psychiatry. 2020. PMID: 33324259 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
